Nachrichten zur Shield Therapeutics PLC Aktie

Shield Therapeutics ‘on track for 2024’

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)’s proposed $10 million equity agreement with AOP Health International Management “should provide some...…

AIM movers: Reassuring trading by Shield Therapeutics and ex-dividends

Main Market miner Hamak Gold (LON: HAMA) has sold its 10.1% stake in Vela Technologies (LON: VELA). These are the…

Shield Therapeutics up 27% after impromptu trading update

Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) surged 27% in early trading after strong October sales of its iron deficiency…

Shield Therapeutics on course in China as sales growth continues

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)) has reported strong sales of iron deficiency drug ACCRUFeR in October, bolstered by an increase…

Shield Therapeutics on track after strong quarter as it looks to raise $10m in new investment

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) reported strong sales for the third quarter of 2024. It unveiled plans to raise around…

Shield Therapeutics shares up 8% after phase III success

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s share price rose 8% following the announcement of successful phase III trial results for its…

Shield Therapeutics hails paediatric phase III study success

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a UK-based pharmaceutical company specialising in treatments for iron deficiency, announced on Wednesday...…

Shield Therapeutics is enjoying significant growth for its iron deficiency product

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag talked with Proactive about the companys impressive...…

Shield Therapeutics growth encouraging, says broker

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) progress was lauded by Peel Hunt in research that followed the speciality pharma groups interims on...…

Shield Therapeutics wraps up strong first half as Accrufer gains more traction in the US

…

Shield Therapeutics a strong period of revenue growth as prescription numbers grow

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) hailed another strong period of growth as it delivered a more than three-fold increase in…

Shield Therapeutics shares up 7% after Canada green light

Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose 7% in early trading following the approval of its drug, Accrufer (ferric maltol), by Health...…

Shield Therapeutics announces approval of ACCRUFeR in Canada

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that Health Canada has approved ACCRUFeR (ferric maltol) as a prescription drug for…

AIM movers: Nexteq hit by destocking and Shield Therapeutics boss leaves

Shield Therapeutics (LON: STX) chief executive Greg Madison is stepping down and non-exec Anders Lundstrom will take over on an…

Shield Therapeutics shares jump 47% as commercial momentum grows

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) shares shot up 47% after it announced a stellar set of second-quarter trading numbers. The update,…

Shield Therapeutics CEO steps down

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said that chief executive Greg Madison is stepping down from the role by mutual consent to pursue…

Shield Therapeutics shares up 7% after $5.7m monetisation deal

Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) were almost 7% higher in afternoon trading after the commercial-stage pharma group fortified…

Shield Therapeutics fortifies balance sheet with $5.7m monetisation deal with biggest shareholder

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…

Shield Therapeutics fortifies balance sheet with $5.7m monetisation deal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…

Shield Therapeutics may receive forecast update following Accrufer application, says broker

Broker Peel Hunt has kept its rating on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) under review following news that its Korean…

Shield Therapeutics files for South Korean regulatory approval for Accrufer

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s partner, Korea Pharma, has filed a New Drug Application (NDA) for Accrufer with the countrys Ministry of...…

Peel Hunt to update Shield Therapeutics’ forecast model

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s full-year results, where the company reported a trebling of total revenues, were consistent with a…

Shield Therapeutics revenues almost treble as Accrufer sales ramp up

Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…

Shield Therapeutics revenues almost treble as Accrufer sales ramp up

Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…

Shield Therapeutics reiterates cash flow positive target as it continues to make US headway

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharmaceutical company, confirmed it is still on course to be cash flow positive…

Shield Therapeutics hails breakthrough year

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) delivered a nearly three-fold increase in its revenues and revealed a strong bank balance as…

Shield Therapeutics is "bearing fruit", says Cavendish

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and…

Shield makes significant commercial traction with prescriptions up 76%

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage specailist pharma company known for its Accrufer iron deficiency treatment, has seen...…

Shield Therapeutics gets positive initiation from broker Stifel

With the growth in popularity of Shield Therapeutics PLCs (AIM:STX, OTCQX:SHIEF) Accrufer prescription iron medicine, Stifel has initiated coverage with a...…

Shield Therapeutics gets positive initiation from broker Stifel

With the growth in popularity of Shield Therapeutics PLCs (AIM:STX, OTCQX:SHIEF) Accrufer prescription iron medicine, Stifel has initiated coverage with a...…

Shield Therapeutics pricing will be "key metric"

…

Shield Therapeutics: Accrufer progressing nicely, new finance put in place

Shield Therapeutics: Accrufer progressing nicely, new finance put in place Year end Dec 31 2021 2022 Revenue…

Shield Therapeutics "couldnt be more pleased" with Viatris collaboration

…

IN BRIEF: Shield Therapeutics prescription orders up in first quarter

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

Shield Therapeutics Shares Rise as US Prescriptions for Accrufer Soar

Shield Therapeutics Shares Rise as US Prescriptions for Accrufer Soar...…

Cytophage Technologies Inc. Board of Directors Welcomes New Member and Board Advisor

COMMERCIALIZATION EXPERT JOINS THE CYTOPHAGE TEAM Winnipeg, Manitoba - TheNewswire - July 6, 2023 - Cytophage Technologies Inc., a Canadian biotech…

AOP Health Gets Minimal Acceptances to Mandatory Offer for Shield Therapeutics

AOP Health Gets Minimal Acceptances to Mandatory Offer for Shield Therapeutics...…